Talmapimod

N/A

Report date: 2023/04/21 14:28:40
NME

Base Information

Drug NameTalmapimod
Drug Alias Nametalmapimodum他玛莫德他美莫德他匹莫德SCIO-469
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitors
TargetsP38 mitogen-activated protein kinase
Therapy Area/IndicationsMyelodysplastic SyndromesBone Marrow DiseasesHematologic Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesScios Inc
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesBone Marrow DiseasesHematologic Diseases +[6] 

Other Information

ATC CodeN/A
Related LinksKEGG